FibroBiologics enters USD 1.2 million convertible debenture deal with Peak One Opportunity Fund
FBLG•FibroBiologics closed a USD 1.2 million convertible debenture deal with Peak One Opportunity Fund on Oct. 8, 2026. Peak One paid USD 1.02 million, reflecting a 15% original issue discount.
1. Debenture terms
The debenture matures Oct. 8, 2027, carries no interest and converts only after default at USD 0.78 per share. FibroBiologics must pay USD 1.08 million on April 8, 2027, followed by USD 60,000 on July 8, 2027. The company also issued 125,000 restricted commitment shares; conversion issuance is capped at 1,671,094 shares without stockholder approval.
